Q4 2025 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Fortis Healthcare Ltd (BOM:532843) reported a consolidated revenue growth of 12.9% for the financial year, with the Hospital business showing a 14.8% increase.
- The company's operating EBITDA margin improved to 20.4% in FY25 from 18.4% in FY24, indicating better operational efficiency.
- The Hospital business saw a significant increase in ARPOB (Average Revenue Per Occupied Bed) by 9%, driven by strong performance in key specialties like oncology and neurosciences.
- Fortis Healthcare Ltd (BOM:532843) successfully acquired the Fortis brand and trademarks, which is expected to positively impact EBITDA margins by approximately 0.3%.
- The company is expanding its bed capacity significantly, with plans to add approximately 2,000 beds over the next few years, enhancing its presence in key regions like Punjab.
- The net debt of Fortis Healthcare Ltd (BOM:532843) increased to INR1,694 crores, with a net debt-to-EBITDA ratio of 0.93x as of March 31, 2025.
- The Diagnostic business showed low single-digit revenue growth, although margins improved, indicating challenges in scaling revenue.
- Certain hospitals within the network, such as those in Jaipur and Vashi, are still underperforming with sub-10% margins, requiring strategic focus for improvement.
- The company faces ongoing legal costs related to the Delhi High Court case, which continue to impact financials.
- There are concerns about geopolitical factors affecting the growth of international patient revenue, which currently contributes 8% to the Hospital business revenue.
Ladies and gentlemen, good day, and welcome to the Q4 FY25 earnings conference call of Fortis Healthcare Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Anurag Kalra, Senior Vice President, Investor Relations at Fortis Healthcare Limited. Thank you, and over to you, sir.
Thank you very much. Very good afternoon, ladies and gentlemen, and thank you for taking the time to join us on our quarter 4 FY25 and FY25 earnings call. The (inaudible) being shared by our MD and CEO, Dr. Ashutosh Raghuvanshi. With him is Mr. Vivek Goyal, our Chief Financial Officer. For (inaudible) , we have Mr. Akshay Tiwari, the CFO of (inaudible) . Unfortunately, Mr. Anand could not join us today, because he is currently in a mix of some travel overseas but we'll be happy to take any questions as well.
We will start with some opening comments by Dr. Raghuvanshi, post which we will open the floor for question and answers. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
